middl
east
respiratori
syndrom
coronaviru
merscov
emerg
infecti
diseas
grow
global
import
caus
sever
acut
respiratori
diseas
peopl
result
death
high
case
fatal
rate
grow
geograph
distribut
vagu
defin
epidemiolog
merscov
creat
urgent
need
effect
public
health
countermeasur
paramount
effect
mean
prevent
vaccin
antibodi
prophylaxi
despit
rel
number
case
todat
research
develop
merscov
vaccin
candid
advanc
quickli
review
survey
landscap
effort
across
multipl
group
academia
govern
industri
middl
east
respiratori
syndrom
merscov
first
isol
septemb
patient
saudi
arabia
present
two
month
earlier
sever
acut
respiratori
infect
acut
renal
failur
retrospect
test
sampl
jordan
identifi
earlier
case
nosocomi
outbreak
april
although
major
merscov
case
occur
saudi
arabia
countri
confirm
import
autochthon
transmit
case
fig
recent
largest
outbreak
outsid
saudi
arabia
occur
south
korea
may
rais
concern
erupt
region
outbreak
acceler
global
spread
similar
phylogenet
relat
sever
acut
respiratori
syndrom
coronaviru
sarscov
kill
nearli
thousand
peopl
decad
earlier
although
definit
host
merscov
yet
establish
close
relat
coronavirus
isol
bat
across
wide
geograph
area
mount
evid
strongli
implic
dromedari
camel
intermedi
anim
reservoir
serolog
survey
throughout
middl
east
north
africa
demonstr
high
preval
merscov
bind
neutral
ab
addit
outbreak
investig
suggest
epidemiolog
linkag
farm
camel
human
case
merscov
spheric
envelop
singlestrand
posit
sens
rna
betacoronaviru
genom
contain
replicas
tel
locu
end
code
structur
protein
toward
end
immunogen
viral
protein
spike
trimer
envelopeanchor
type
fusion
glycoprotein
interfac
human
host
cognat
receptor
dipeptidyl
peptidas
mediat
viral
entri
compris
two
subunit
contain
receptorbind
domain
determin
cell
tropism
locat
cell
fusion
machineri
although
broad
tissu
distribut
clinic
manifest
merscov
attribut
local
lower
respiratori
tract
much
like
coronavirus
merscov
also
caus
signific
dysfunct
gastrointestin
cardiovascular
renal
neurolog
system
merscov
distinct
though
tendenc
caus
greatest
harm
older
individu
concurr
comorbid
one
organsystem
despit
past
effort
develop
coronaviru
countermeasur
respons
sarscov
pandem
current
prophylact
therapeut
intervent
proven
efficaci
merscov
coronaviru
infect
although
combin
treatment
ribavirin
interferon
shown
improv
clinic
outcom
merscovinfect
nonhuman
primat
nhp
treatment
initi
soon
viral
challeng
h
result
replic
human
fact
experiment
intervent
demonstr
appreci
benefit
acut
ill
patient
consist
control
manner
rapidli
scale
treatment
base
natur
occur
neutral
antibodi
convalesc
plasma
hyperimmun
globulin
hand
demonstr
mortal
reduct
respiratori
infect
may
hold
promis
merscov
well
develop
howev
limit
logist
challeng
local
technic
capac
donor
suppli
support
manag
adapt
guidelin
develop
sarscov
thu
far
mainstay
merscov
treatment
global
develop
coronaviru
vaccin
fade
aftermath
sarscov
pandem
sinc
gain
renew
momentum
face
current
merscov
outbreak
previou
approach
coronaviru
vaccin
develop
broad
includ
wholeinactiv
liveattenu
virus
recombin
vector
protein
subunit
well
dna
rna
base
platform
develop
base
immunogen
design
surfac
glycoprotein
primari
target
neutral
antibodi
natur
coronaviru
infect
number
preclin
clinic
studi
show
sarscov
protein
subunit
specif
rbd
core
could
serv
domin
target
neutral
antibodi
mice
nonhuman
primat
human
therefor
becam
basi
number
promis
sarscov
vaccin
candid
protein
subunit
rbd
also
basi
sever
merscov
vaccin
candid
fig
resolut
rbd
crystal
structur
alon
complex
receptor
inform
design
immunogen
express
either
recombin
protein
fragment
conjug
fragment
crystalliz
fc
region
human
antibodi
type
construct
formul
aluminum
salt
oilinwat
adjuv
elicit
neutral
antibodi
high
potenc
across
multipl
viral
strain
despit
demonstr
immunogen
anim
model
anticip
safeti
human
rbd
base
vaccin
candid
limit
epitop
breadth
although
coronaviru
genom
variabl
rna
virus
rbd
mutabl
region
contain
mutat
site
defin
antibodi
escap
variant
thu
vaccin
candid
elicit
divers
antibodi
repertoir
well
robust
cellular
immun
respons
may
offer
advantag
broader
durabl
protect
fulllength
use
immunogen
could
least
increas
breadth
antibodi
respons
howev
difficult
express
may
requir
addit
work
produc
stabl
solubl
trimer
ectodomain
investig
univers
maryland
collabor
novavax
inc
overcom
problem
develop
rosett
stabl
immunogen
murin
model
vaccin
mimic
natur
infect
liveattenu
virus
recombin
viral
vector
may
elicit
even
robust
immun
live
attenu
virus
histor
among
immunogen
platform
avail
capac
present
multipl
antigen
across
viral
life
cycl
nativ
conform
although
liveattenu
merscov
yet
test
one
construct
potenti
protect
howev
manufactur
liveattenu
virus
requir
contain
biosafeti
level
facil
addit
liveattenu
virus
carri
hazard
inadequ
attenu
revers
wild
type
form
caus
dissemin
diseas
particularli
immunocompromis
host
given
moder
immunocompromis
adult
comorbid
diabet
mellitu
chronic
kidney
diseas
suffer
sever
merscov
diseas
individu
may
compris
target
popul
immun
thu
make
liveattenu
viru
vaccin
less
viabl
option
replic
compet
viral
vector
could
pose
similar
threat
dissemin
diseas
immunosuppress
replic
defici
vector
howev
avoid
risk
maintain
advantag
nativ
antigen
present
elicit
cell
immun
abil
express
multipl
antigen
date
two
recombin
vector
platformsmodifi
although
replic
defici
vector
rel
safe
immunogen
abil
deliv
genet
materi
express
could
imped
preexist
develop
immun
vector
one
way
overcom
limit
administ
differ
vector
socal
primeboost
immun
regimen
strategi
effect
pathogen
like
success
could
recapitul
merscov
use
one
type
platform
antigen
singl
vaccin
also
increas
likelihood
induc
broad
repertoir
antibodi
divers
mechan
viral
neutral
one
vaccin
regimen
develop
us
nation
institut
health
base
fulllength
dna
truncat
subunit
glycoprotein
elicit
neutral
antibodi
mice
direct
outsid
rbdand
subunit
immun
construct
also
protect
nhp
sever
lung
diseas
intratrach
challeng
merscov
dnaonli
vaccin
express
multipl
antigen
also
develop
inovio
pharmaceut
geneon
life
scienc
inc
advanc
phase
firstinhuman
trial
vaccin
candid
mention
develop
prophylact
use
howev
total
number
case
reproduct
rate
merscov
rel
low
difficult
defin
target
popul
vaccin
would
support
invest
manufactur
advanc
product
develop
also
low
incid
lack
robust
anim
model
would
difficult
achiev
vaccin
efficaci
result
would
suffici
support
licensur
human
mab
hand
could
use
without
much
discrimin
outbreak
set
postexposur
prophylaxi
earli
treatment
advantag
mab
polyclon
antibodi
administ
convalesc
plasma
hyperimmun
globulin
higher
potenc
greater
specif
extens
prelicens
evalu
consequ
improv
safeti
profil
addit
mab
help
defin
immunogen
epitop
crystallograph
analysi
therebi
provid
atom
level
detail
design
better
immunogen
howev
timelin
mab
develop
may
longer
potenti
cost
vaccin
despit
requir
greater
upfront
invest
sever
group
develop
highli
potent
mab
current
advanc
preclin
stage
test
fig
isol
immun
anim
micehuman
micenhp
other
identifi
either
antibodi
human
phage
librari
memori
b
cell
infect
recov
human
survivor
almost
mab
report
target
spike
rbd
like
mab
direct
site
spike
glycoprotein
recov
potent
neutral
publish
bind
recombin
spike
picomolar
affin
neutral
merscov
pseudoviru
half
maxim
inhibitori
concentr
ic
mcgl
less
addit
demonstr
protect
efficaci
preand
postexposur
prophylaxi
anim
model
success
thu
far
isol
potent
protect
mab
may
prove
use
therapeut
develop
target
popul
well
defin
may
prove
challeng
advanc
product
licensur
fullscal
product
afford
cost
purpos
prophylaxi
yet
undefin
popul
vagu
defin
epidemiolog
merscov
complic
design
implement
appropri
public
health
countermeasur
transmiss
event
occur
either
set
household
cluster
nosocomi
outbreak
also
like
viru
introduc
multipl
time
human
popul
larg
zoonot
reservoir
ie
dromedari
camel
given
broad
distribut
ownership
camel
arabian
peninsula
case
occur
target
vaccin
campaign
may
prove
difficult
outbreak
republ
korea
reveal
patient
worker
healthcar
facil
infect
patient
high
risk
secondari
acquisit
optim
strategi
may
use
vaccin
conjunct
stringent
infect
control
practic
hospit
merscov
case
treat
epidemiolog
link
merscov
bat
camel
human
present
opportun
veterinari
vaccin
interrupt
transmiss
cycl
success
preced
socal
onehealth
approach
toward
mitig
human
diseas
veterinari
vaccin
exist
exampl
equivac
hendra
viru
vaccin
develop
sole
hors
although
hendra
viru
even
rare
merscov
highli
fatal
treatment
intens
support
manag
protein
subunit
vaccin
licens
rolledout
australia
outbreak
viru
occur
sinc
time
incid
hors
fallen
precipit
human
case
detect
similar
strategi
may
applic
merscov
howev
veterinari
vaccin
context
would
deploy
sole
sake
protect
human
viru
caus
mild
upper
respiratori
ill
camel
safeti
reduct
viral
shed
would
demonstr
immun
challeng
transmiss
studi
camel
camelid
popul
one
shown
efficaci
one
primari
challeng
develop
countermeasur
merscov
lack
appropri
anim
model
recapitul
natur
histori
human
diseas
much
difficulti
origin
absenc
viru
cognat
receptor
one
group
approach
problem
success
transduc
mice
adenovir
vector
express
human
although
relev
standard
murin
model
transient
transduct
desir
protein
may
result
inconsist
tissu
express
adenoviru
antigen
agraw
et
al
made
import
advanc
develop
transgen
mous
model
demonstr
product
dissemin
merscov
infect
although
rhesu
macaqu
manifest
full
clinic
diseas
develop
transient
lower
respiratori
infect
quantifi
evalu
comput
tomographi
investig
nih
rocki
mountain
laboratori
rml
integr
research
facil
irf
also
independ
develop
potenti
lethal
marmoset
model
could
use
evalu
vaccin
mab
therapeut
merscov
vaccinesboth
activ
passivear
develop
test
relev
anim
model
requir
also
need
detail
understand
epidemiolog
immunolog
pathogenesi
viru
aftermath
west
african
ebola
viru
epidem
face
current
zika
viru
outbreak
global
health
commun
coalesc
around
realiz
multifacet
plan
requir
quickli
effici
respond
global
public
health
emerg
world
health
organ
current
develop
blueprint
prepar
respons
follow
merscov
highlight
case
studi
although
merscov
still
caus
rel
case
limit
geograph
distribut
high
case
fatal
sudden
outbreak
korea
proven
pathogen
public
health
concern
concentr
epidem
saudi
arabia
also
rais
specter
intern
spread
everi
year
hajj
one
largest
mass
gather
event
world
ultim
develop
safe
effect
vaccin
merscov
may
yield
greatest
benefit
current
epidem
knowledg
gain
creat
platform
combat
coronavirus
whole
opinion
express
herein
author
constru
offici
repres
view
us
depart
defens
depart
armi
